Practice guidelines for monitoring the safety of tofacitinib (according to the proceedings of the Expert Council resolution dated 14 October 2014, Moscow)

Современная ревматология

关键词: expert council;    resolution;    tofacitinib;    therapy safety monitoring;   

DOI  :  10.14412/1996-7012-2015-3-73-79

来源: DOAJ

【 摘 要 】

The Meeting of the Expert Council considered in detail the key aspects associated with the possible development of adverse reactions during therapy with tofacitinib (TOFA). Active discussion gave rise to a resolution that summarized the main facts concerning the safety of TOFA and gave practical recommendations for the screening and monitoring of infections, cardiovascular diseases and other key areas requiring that exclusive control should be exercised during this therapy. TOFA is the first drug from a new group of immunomodifying and anti-inflammatory drugs, intracellular kinase inhibitors. As of now, it is the only drug that belongs to a class of the so-called small molecules, which is approved for the treatment of rheumatoid arthritis in the Russian Federation and a number of other countries. TOFA is a low molecular weight drug for oral administration; however, its unique mechanism of action brings it close to that of biological agents. A broad spectrum of biological effects of TOFA and its potential effect on a number of important physiological processes demand for special attention to the safety of its therapy.

【 授权许可】

Unknown